Enliven Therapeutics, Inc.
ELVN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $80,778 | $64,574 | $31,022 | $20,474 |
| G&A Expenses | $23,776 | $18,955 | $7,769 | $4,288 |
| SG&A Expenses | $23,776 | $18,955 | $7,769 | $4,288 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $104,554 | $83,529 | $38,791 | $24,762 |
| Operating Income | -$104,554 | -$83,529 | -$38,791 | -$24,762 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15,762 | $11,945 | $1,129 | $22 |
| Pre-Tax Income | -$88,792 | -$71,584 | -$37,662 | -$24,740 |
| Tax Expense | $232 | $0 | $0 | $0 |
| Net Income | -$89,024 | -$71,584 | -$37,662 | -$24,740 |
| % Margin | – | – | – | – |
| EPS | -1.89 | -2.01 | -6.03 | -3.17 |
| % Growth | 6% | 66.7% | -90.2% | – |
| EPS Diluted | -1.89 | -2.01 | -6.03 | -3.17 |
| Weighted Avg Shares Out | 47,073 | 35,546 | 6,249 | 7,814 |
| Weighted Avg Shares Out Dil | 47,073 | 35,546 | 6,249 | 7,815 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,891 | $11,967 | $1,129 | $22 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $317 | $297 | $215 | $115 |
| EBITDA | -$104,237 | -$83,232 | -$38,576 | -$24,647 |
| % Margin | – | – | – | – |